Thiazolidinediones for type 2 diabetes. All glitazones may exacerbate heart failure.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

14 citing papers in PubMed, 44 citations in OpenAlex.

1. Hypothesis: Nutrient Off-Loading and Ectopic Fat Reduction Reverse Insulin Resistance and Improve Cardiovascular Outcomes in Type 2 Diabetes-A Narrative Review.International journal of molecular sciences · 2026
   Review
2. Effects of treatment of non-alcoholic fatty liver disease on heart failure with preserved ejection fraction.Frontiers in cardiovascular medicine · 2022
   Review
3. Heart failure and diabetes: metabolic alterations and therapeutic interventions: a state-of-the-art review from the Translational Research Committee of the Heart Failure Association-European Society of Cardiology.European heart journal · 2018
   Article
4. Cardiovascular safety of dipeptidyl peptidase-4 inhibitors: recent evidence on heart failure.American journal of translational research · 2016
   Article
5. Thiazolidinediones and Edema: Recent Advances in the Pathogenesis of Thiazolidinediones-Induced Renal Sodium Retention.PPAR research · 2015
   Review
6. Metformin in Diabetic Patients with Heart Failure: Safe and Effective?Current cardiovascular risk reports · 2013
   Article
7. Complications of diabetes therapy.Endocrinology and metabolism clinics of North America · 2013
   Review
8. Prescribing of rosiglitazone and pioglitazone following safety signals: analysis of trends in dispensing patterns in the Netherlands from 1998 to 2008.Drug safety · 2012
   Article
9. Idealized PPARγ-Based Therapies: Lessons from Bench and Bedside.PPAR research · 2012
   Article
10. After avandia: the use of antidiabetic drugs in patients with heart failure.Texas Heart Institute journal · 2012
    Review
11. Insulin sensitizers and heart failure: an engine flooded with fuel.Current hypertension reports · 2010
    Article
12. Combined thiazolidinedione-insulin therapy: should we be concerned about safety?Drug safety · 2004
    Review
13. The role of sulphonylureas in the management of type 2 diabetes mellitus.Drugs · 2004
    Review
14. The role of the angiotensin system in cardiac glucose homeostasis: therapeutic implications.Drugs · 2002
    Review

Corrections and comments

• Comment on
  Thiazolidinediones for type 2 diabetes. New agents reduce insulin resistance but need long term clinical trials.2000

Authors and funding

3 authors at 1 institution in 1 country.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as